CClinicalTrials.gg
CompletedNCT03278587VIEW II PilotUpdated May 4, 2026

Village-Integrated Eye Worker Trial II - Pilot

An interventional study of Community-based screening program and Cataract camp program in Cataract, Glaucoma and Age Related Macular Degeneration, sponsored by University of California, San Francisco. Completed at 1 site in Nepal. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
87,992
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Loss of vision from these conditions is not inevitable; however, identifying at-risk cases and linking cases with appropriate care remain significant challenges.

Eye health care systems must determine optimal strategies for reaching people outside of their immediate orbit in order to reduce visual impairment. Visual impairment can be reduced by case detection of prevalent disease like cataract and refractive error, or by screening for early disease like glaucoma, AMD, and DR and preventing progression. Systems around the world have developed numerous approaches to both case detection and screening but there is very little research to support the choice of allocating resources to case detection or screening and little data exists on the cost effectiveness of the various approaches to each.

VIEW II Pilot is a cluster-randomized trial to determine the effectiveness of different approaches to community-based case detection and screening for ocular disease. Communities will be randomized to one of four arms: 1) a comprehensive ocular screening program, 2) a cataract camp-based program, 3) a community health worker-based program, and 4) no program.

Read the detailed description

Specific Aim 1: to determine whether screening leads to increased visual acuity compared to the cataract camp approach.

Specific Aim 2: to determine whether a community health volunteer program increases the rate of cataract surgery compared to a no program.

02

Conditions studied

  • Cataract
  • Glaucoma
  • Age Related Macular Degeneration
  • Diabetic Retinopathy
  • Refractive Errors
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria(community-level):

  • Wards in the Chitwan and Nawalparasi districts that participated in the VIEW trial and have not received a cataract camp in the past 6 months.

Inclusion Criteria (individual-level):

  • Individuals aged 50 and older will be eligible to participate in the screening program, cataract camp programs, and the FCHV program
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
87,992 participants (actual)

Study arms

  • Active comparator
    Community-based screening

    Other: Community-based screening program

  • Active comparator
    Cataract camp program

    Other: Cataract camp program

  • Active comparator
    Community health worker program

    Other: Community health worker program

  • No intervention
    No intervention

Interventions

  • OtherCommunity-based screening program

    In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.

  • OtherCataract camp program

    In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.

  • OtherCommunity health worker program

    In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.

05

What researchers measure

Primary outcomes

  1. Visual acuity

    Primary outcome for specific aim 1, comparison between screening and case detection arms

    Time frame: 1 year

  2. Cataract surgical rate

    Primary outcome for specific aim 2, comparison between community health worker program and no program arms

    Time frame: 1 year

Secondary outcomes

  1. Cost-effectiveness

    Cost-effectiveness of all 4 arms will be assessed

    Time frame: 1 year

  2. Visual acuity

    Visual acuity of population 50 years and older in all arms will be compared

    Time frame: 1 year

  3. Number of cases of ocular disease detected

    Number of cases of ocular disease in the screening and case detection arms will be compared

    Time frame: 1 year

06

Study locations

1 site
  • Bharatpur Eye Hospital
    Bharatpur, Chitwan, Nepal
07

Registry details

Key details

Study ID
NCT03278587
Lead sponsor
University of California, San Francisco
Collaborators
Seva Foundation
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
May 31, 2018
Primary completion
Feb 12, 2023
Completion
Feb 12, 2023
Last update
May 4, 2026

Study contacts

Jeremy D Keenan, MD, MPH
principal investigator · University of California, San Francisco

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion